Last reviewed · How we verify

Lopressor — Competitive Intelligence Brief

Lopressor (metoprolol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-1 selective blocker. Area: Cardiovascular.

marketed Beta-1 selective blocker Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Lopressor (metoprolol) — Generic (originally Ciba-Geigy/Novartis). Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lopressor TARGET metoprolol Generic (originally Ciba-Geigy/Novartis) marketed Beta-1 selective blocker Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A 1978-08-07

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-1 selective blocker class)

  1. Generic (originally Ciba-Geigy/Novartis) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lopressor — Competitive Intelligence Brief. https://druglandscape.com/ci/metoprolol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: